New evidence for beneficial effects of statins unrelated to lipid lowering: Editorial

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 21, Issue 1, 2001, Pages 3-5

  Palinski, Wulf ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Atherosclerosis; Chronic and acute inflammation; HMG CoA inhibitors; Immune system; In vivo

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; STATIN;

ATHEROSCLEROSIS; DRUG EFFECT; EDITORIAL; ENZYME INHIBITION; HYPERCHOLESTEROLEMIA; IMMUNE SYSTEM; LIPID BLOOD LEVEL; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS;

EID: 0035174867     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.atv.21.1.3     Document Type: Editorial

References (33)

1. Current perspectives on statins
2. George Lyman Duff memorial lecture: Arterial imaging and atherosclerosis reversal
3. Antiatherothrombotic properties of statins: Implications for cardiovascular event reduction
4. State-of-the-art lecture: Statins and blockers of the renin-angiotensin system: Vascular protection beyond their primary mode of action
5. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors
6. Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase
7. Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase
8. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors increase fibrinolytic activity in rat aortic endothelial cells: Role of geranylgeranylation and Rho proteins
9. 3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors attenuate vascular smooth muscle proliferation by preventing rho GTPase-induced down-regulation of p27(Kip1)
10. 3-Hydroxy-3-methylglutaryl coenzyme A reductase and isoprenylation inhibitors induce apoptosis of vascular smooth muscle cells in culture
11. Inhibition of monocyte chemotactic protein-1 synthesis by statins
12. Protein lipidation in cell signaling
13. Integrin-dependent leukocyte adhesion involves geranylgeranylated protein(s)
14. Current concepts in cardiovascular pathology: The role of LDL cholesterol in plaque rapture and stabilization
15. Genetic evidence for a common pathway mediating oxidative stress, inflammatory gene induction, and aortic fatty streak formation in mice
16. Apoptosis reduced by mildly oxidized LDL involves multiple apoptotic signaling pathways in human coronary cells
17. Effect of pravastatin on outcomes after cardiac transplantation
18. Simvastatin reduces graft vessel disease and mortality after heart transplantation: A four-year randomized trial
19. HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis
20. Long-term effects of pravastatin on plasma concentration of C-reactive protein
21. Simvastatin has anti-inflammatory and antiatherosclerotic activities independent of plasma cholesterol lowering
22. Feedback regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase in livers of mice treated with mevinolin, a competitive inhibitor of the reductase
23. HMG-CoA reductase inhibitors decrease CD11b expression and CD11b-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolemia
24. Simvastatin preserves the ischemic-reperfused myocardium in normocholesterolemic rat hearts
25. Lovastatin and phenylacetate inhibit the induction of nitric oxide synthase and cytokines in rat primary astrocytes, microglia, and macrophages
26. Amelioration of experimental allergic encephalomyelitis in Lewis rats by lovastatin
27. Hydroxymethylglutaryl coenzyme A reductase inhibitors modify the inflammatory response of human macrophages and endothelial cells infected with Chlamydia pneumoniae
28. Lipophilic HMG-CoA reductase inhibitor has an anti-inflammatory effect: Reduction of mRNA levels for intefieukin-1β, interleukin-6, cyclooxygenase-2, and p22phox by regulation of peroxisome proliferator-activated receptor-α (PPAR-α) in primary endothelial cells
29. Peroxisome proliferator-activated receptor γ ligands inhibit development of atherosclerosis in LDL receptor-deficient mice
30. Statins as a newly recognized type of immunosuppressor
31. Regulation of MHC class II expression by interferon-γ mediated by the transactivator gene CIITA
32. Immunomodulation: A new role for statins?
33. Immune responses to oxidative neoepitopes on LDL and phospholipids modulate the development of atherosclerosis